Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
Income Statement
Follow revenue through to earnings.
Revenue
$16.80M
FY 2025 · Annual
Operating Income
-$32.43M
FY 2025 · Annual
Net Income
-$43.32M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 16.8M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 9.37M |
| Gross Profit | 0 | 0 | 0 | 0 | 7.43M |
| Gross Margin | — | — | — | — | 44.2% |
| Research & Development | 209.05K | 391.73K | 2.58M | 1.18M | 1.23M |
| Selling, General & Admin | 629.95K | 1.93M | 4.28M | 6.39M | 37.08M |
| Operating Expenses | 839K | 2.32M | 6.86M | 7.57M | 39.86M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 2.29M |
| EBITDA | (595.13K) | (2.32M) | (6.86M) | (7.17M) | (45.41M) |
| EBITDA Margin | — | — | — | — | -270.4% |
| Operating Income | (839K) | (2.32M) | (6.86M) | (7.57M) | (32.43M) |
| Operating Margin | — | — | — | — | -193.1% |
| Interest Income | 0 | 0 | 0 | 0 | 5K |
| Interest Expense | 253 | 140.43K | 518.51K | 786.39K | 3.01M |
| Other Income / Expenses | 243.61K | (140.43K) | (518.51K) | (383.89K) | (18.28M) |
| Income Before Tax | (595.39K) | (2.46M) | (7.38M) | (7.96M) | (50.71M) |
| Pre-Tax Margin | — | — | — | — | -301.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (7.39M) |
| Net Income | (595.39K) | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Net Margin | — | — | — | — | -257.9% |
| EPS (Basic) | (1.00) | (4.26) | (12.80) | (13.54) | (23.04) |
| EPS (Diluted) | (1.00) | (4.26) | (12.80) | (13.54) | (23.04) |
| 576.75K | 576.75K | 576.75K | 587.62K | 1.88M | |
| 576.75K | 576.75K | 576.75K | 587.62K | 1.88M |
PTHS Earnings Waterfall · TTM
AMEX:PTHS · Revenue to Net Income
Key Ratios
Analysis
$27.7M of revenue converted into -$51.6M of net income for the selected period. Gross margin is 34.3% and net margin is -136.0%, showing how much revenue survives after costs and taxes. EPS is $-40.69, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | May 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 26, 2026 | |
| 144 | Notice of proposed sale of securities | May 22, 2026 | |
| 8-K | Current report | May 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 18, 2026 |
How much revenue does PTHS generate?
Pelthos Therapeutics Inc. (PTHS) reported $16.80M of revenue in fiscal 2025.
Is PTHS profitable?
Pelthos Therapeutics Inc. (PTHS) reported -$43.32M of net income, with a net margin of -257.9%.
Continue the stock analysis
Jump to another research area for this company.